1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E4B7BEB0B6C78275652582B9002877C0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/understanding-future-trends-changing-landscape-real-world-evidence-generation
18
19
203.94.129.211
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Health Outcomes

Real World Evidence: Understand Trends & Seize Opportunities in the Changing Landscape of RWE Generation

ID: POP-294


Features:

23 Info Graphics

106 Data Graphics

960+ Metrics


Pages: 143


Published: 2018


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Forward-looking pharmaceutical companies are taking rapid steps to boost their internal Real World Evidence (RWE) capabilities to better inform payers and their formulary and reimbursement decisions.

Best Practices, LLC undertook this benchmarking research to examine key trends and vital opportunities for pharma in the changing landscape of Real World Evidence generation. This
report benchmarks 16 RWE study methods for current and future study utilization, provide insights into successful data collection methods, outsourcing levels, critical vendor attributes and resourcing trends.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Abbvie; Allergan; AstraZeneca; Bayer; Celldex Therapeutics; Dermira; EMD Serono; Flexion Therapeutics; GlaxoSmithKline ; Grifols; Janssen; Johnson & Johnson; Merck; Novartis; Sanofi; UCB Pharma; Vifor Pharma; Genzyme

Study Snapshot

Best Practices, LLC engaged 25 leaders with deep experience in managing Real World Evidence generation at 19 leading pharmaceutical companies in this benchmarking research.


Key topics covered in this report include:

  • Real World Evidence Study Methods Utilized
  • Methods of Data Collection
  • Outsourcing
  • Real World Evidence Budget
  • Utilization of Vendors for Real World Evidence Generation


Key Findings

Sample key insights uncovered from this report are noted below. Detailed findings are available in the full report.


1. Current and Future RWE Study Utilization
  • Overview: Study methods that will be utilized the most in the future are Prospective Observational, Health Economic Modeling, Health Economic/HTA, Medical Record Abstraction, Drug Utilization Studies, and Disease Registries
  • Economic/Reimbursement Studies: These RWE studies are the most utilized by respondents; future use to grow 26%
  • Observational Studies: Three of the five studies in this category will be used by +70% of respondents in the future
  • Extension Studies: This category of RWE studies used little but will Increase the most in use; future use to jump 123%

2. Data Collection Methods
  • Overview: A mix of primary & secondary data is a widely used data collection method for 9 of 16 RWE study types

3. Utilization of Outsourcing for RWE Studies
  • Overview: A majority of respondents use a mix of in-house and outsourcing for 12 (75%) of the 16 RWE studies

4. Desired Vendor Traits
  • Overview: Experience on Similar Studies, Scientific Expertise, & Prior Experience with Vendor are top 3 vendor traits

Table of Contents

I.Executive Summary: Methodology, Participants, Recommendations & Key Findingspgs. 3-18
Universe of Learning: Benchmark Class
Study Structure & Design
Study Recommendations and Findings
II.Overview of RWE Study Methods Utilization, Data Collection Methods & Outsourcingpgs. 19-39
Economic / Reimbursement Studies Category
Observational Studies Category
Non-Safety Registries Category
Intervention Studies Category
Extension Studies Category
III.RWE Budget and Rationale for Outsourcingpgs. 40-46
Average Spent on RWE Vendors
Rationale for Using Outsourcing
IV.Economic / Reimbursement Studiespgs. 47-57
V.Observational Studiespgs. 58-83
VI.Non-Safety Registries Studiespgs. 84-104
VII.Intervention Studiespgs. 105-120
VIII.Extension Studiespgs. 121-131
IX.Benchmark Class Profilepgs. 132-137
X.Appendixpgs. 138-143

    List of Charts & Exhibits

    I. Executive Summary
    • Understanding future trends in the changing landscape of real world evidence generation
    • Six RWE study methods that pharma will heavily utilize in the future
    • RWE study methods with most growth potential
    • Current and future use of RWE Studies
    • Top vendor traits: Experience with similar studies and scientific expertise

    II. Overview of RWE Study Methods Utilization, Data Collection Methods, Outsourcing & Vendor Selection
    • Economic / reimbursement studies – Current, past and future utilization; current and future growth potential; outsourcing
    • Current and future use of economic / reimbursement studies
    • Data collection methods utilized and future preference for the same for economic / reimbursement studies
    • Top vendor traits for selecting a vendor for economic / reimbursement studies
    • Observational studies category - Current, past and future utilization; current and future growth potential; outsourcing
    • Current and future use of observational studies
    • Data collection methods utilized and future preference for data collection method for observational studies
    • Top vendor traits for selecting a vendor for observational studies
    • Non-safety registries category - Current, past and future utilization; current and future growth potential; outsourcing
    • Current and future use of non-safety registries
    • Data collection methods utilized and future preference for data collection method for non-safety registries
    • Top vendor traits for selecting a vendor for non-safety registries
    • Intervention studies category - Current, past and future utilization; current and future growth potential; outsourcing
    • Current and future use of intervention studies
    • Data collection methods utilized and future preference for data collection method for intervention studies
    • Top vendor traits for selecting a vendor for intervention studies
    • Extension studies - Current, past and future utilization; current and future growth potential; outsourcing
    • Current and future use of extension studies
    • Data collection methods utilized and future preference for data collection method for extension studies
    • Top vendor traits for selecting a vendor for extension studies

    III. RWE Budget & Rationale for Outsourcing
    • Budget allocation for RWE generation and anticipated RWE generation budget in 2020
    • Rationale for using in-house resources for RWE generation
    • Rationale for using outsourcing approach
    • Rationale for using mix resourcing approach
    • The deciding factor for in-house or outsourcing RWE work

    IV. Economic / Reimbursement Studies
    • Current and future utilization level for health economic modeling study method
    • Number of studies conducted using health economic modeling method and anticipated use of health economic modeling study method
    • Data collection methods utilized for health economic modeling studies and future preference
    • Current and future utilization of outsourcing for health economic modeling studies
    • Vendor selection criteria and vendor preference for health economic modeling studies
    • Current and future utilization level for health economic / health technology assessment (HTA) dossier study method
    • Number of studies conducted using health economic / health technology assessment (HTA) dossier method and anticipated use health economic / HTA dossier study method
    • Data collection methods utilized for health economic / HTA dossier studies and future preference
    • Current and future utilization of outsourcing for health economic / HTA dossier studies
    • Vendor selection criteria and vendor preference for health economic / HTA dossier studies

    V. Observational Studies
    • Current and future utilization level for post-authorization safety studies
    • Number of studies conducted using post-authorization safety method and anticipated use of post-authorization safety study method
    • Data collection methods utilized for post-authorization safety studies and future preference
    • Current and future utilization of outsourcing for post-authorization safety studies
    • Vendor selection criteria and vendor preference for post-authorization safety studies
    • Current and future utilization level for drug utilization studies
    • Number of studies conducted using drug utilization study method and anticipated use of drug utilization study method
    • Data collection methods utilized for drug utilization studies and future preference
    • Current and future utilization of outsourcing for drug utilization studies
    • Vendor selection criteria and vendor preference for drug utilization studies
    • Current and future utilization level for prospective observational studies with HEOR objectives
    • Number of studies conducted using the method of prospective observational studies with HEOR objectives and anticipated use of prospective observational studies with HEOR objectives
    • Data collection methods utilized for prospective observational studies with HEOR objectives and future preference
    • Current and future utilization of outsourcing for prospective observational studies with HEOR objectives
    • Vendor selection criteria and vendor preference for prospective observational studies with HEOR objectives
    • Current and future utilization level for post-authorization efficacy studies
    • Number of post-authorization efficacy studies conducted and anticipated use of post-authorization efficacy studies
    • Data collection methods utilized for post-authorization efficacy studies and future preference
    • Current and future utilization of outsourcing for post-authorization efficacy studies
    • Vendor selection criteria and vendor preference for post-authorization efficacy studies
    • Current and future utilization level for medical record abstraction / retrospective chart reviews
    • Number of studies conducted using the method of medical record abstraction / retrospective chart reviews and anticipated use of medical record abstraction / retrospective chart reviews
    • Data collection methods utilized for medical record abstraction / retrospective chart reviews and future preference
    • Current and future utilization of outsourcing for medical record abstraction / retrospective chart reviews
    • Vendor selection criteria and vendor preference for medical record abstraction / retrospective chart reviews

    VI. Non-Safety Registries
    • Current and future utilization level for disease registries
    • Number of disease registry studies conducted and anticipated use of disease registries
    • Data collection methods utilized for disease registries and future preference
    • Current and future utilization of outsourcing for disease registries
    • Vendor selection criteria and vendor preference for disease registries
    • Current and future utilization level for product registries (not including vaccine registries)
    • Number of product registry (not including vaccine registry) studies conducted and anticipated use of product registries (not including vaccine registries)
    • Data collection methods utilized for product registries (not including vaccine registries) and future preference
    • Current and future utilization of outsourcing for product registries (not including vaccine registries)
    • Vendor selection criteria and vendor preference for product registries (not including vaccine registries)
    • Current and future utilization level for pregnancy registries
    • Number of pregnancy registry studies conducted and anticipated use of pregnancy registries
    • Data collection methods utilized for pregnancy registries and future preference
    • Current and future utilization of outsourcing for pregnancy registries
    • Vendor selection criteria and vendor preference for pregnancy registries
    • Current and future utilization level for vaccine registries
    • Number of vaccine registry studies conducted and anticipated use of vaccine registries
    • Data collection methods utilized for vaccine registries and future preference
    • Current and future utilization of outsourcing for vaccine registries
    • Vendor selection criteria for vaccine registries

    VII. Intervention Studies
    • Current and future utilization level for expanded access programs
    • Number of expanded access programs conducted and anticipated use of expanded access programs
    • Data collection methods utilized for expanded access programs and future preference
    • Current and future utilization of outsourcing for expanded access programs
    • Vendor selection criteria and vendor preference for expanded access programs
    • Current and future utilization level for randomized pragmatic trials
    • Number of randomized pragmatic trials conducted and anticipated use of randomized pragmatic trials
    • Data collection methods utilized for randomized pragmatic trial and future preference
    • Current and future utilization of outsourcing for randomized pragmatic trial
    • Vendor selection criteria and vendor preference for randomized pragmatic trial
    • Current and future utilization level for other low-intervention clinical trials
    • Number of other low-intervention clinical trials conducted and anticipated use of other low-intervention clinical trials
    • Data collection methods utilized for other low-intervention clinical trial and future preference
    • Current and future utilization of outsourcing for other low-intervention clinical trial
    • Vendor selection criteria and vendor preference for other low-intervention clinical trial

    VIII. Extension Studies
    • Current and future utilization level for concurrent outcomes studies
    • Number of concurrent outcomes studies conducted and anticipated use of concurrent outcomes studies
    • Data collection methods utilized for concurrent outcomes studies and future preference
    • Current and future utilization of outsourcing for concurrent outcomes studies
    • Vendor selection criteria and vendor preference for concurrent outcomes studies
    • Current and future utilization level for extension studies
    • Number of extension studies conducted and anticipated use of extension studies
    • Data collection methods utilized for extension studies and future preference
    • Current and future utilization of outsourcing for extension studies
    • Vendor selection criteria and vendor preference for extension studies

    IX. Benchmark Class Profile
    • Benchmark partners’ geographic responsibility for RWE generation
    • Therapeutic area responsibility of benchmark participants
    • Benchmark partners’ organizational and product type responsibility
    • Portfolio responsibility of benchmark participants
    • Functional area responsibility of benchmark partners

    X. Appendix
    • RWE study methods with significant growth opportunities in future
    • Definitions of RWE study types